Benchmark Maintains a 'Buy' on Synergetics USA (SURG); Recent Dip Offers Opportunity
Tweet Send to a FriendGet Alerts SURG Hot Sheet
Price: $3.16 +0.96%
Rating Summary:
1 Buy, 3 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 11 | Down: 35 | New: 23
Rating Summary:
1 Buy, 3 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 11 | Down: 35 | New: 23
Trade SURG Now!
Benchmark maintains a 'Buy' on Synergetics USA (NASDAQ: SURG) price target of $8.00.
Analyst, Raymond Myers, said, "Meeting with Management at the Benchmark Investor One-on-One Conference on May 31 strengthen our conviction that the recently pre-announced F3Q miss is a short term distraction to an otherwise sound strategic outlook. In the near-term, Management is confident that current quarter results will return to their historically robust growth trajectory. More important, Synergetics is making inroads with VersaPACK and is confident in VersaVIT’s approval in as little as 30-days. Advancing these key strategic initiatives outweighs short term quarterly inconsistency, in our view. We believe last week’s stock reaction creates an outstanding buying opportunity with SURG shares trading at 8.5x EV/EPS forecast in F2013."
For an analyst ratings summary and ratings history on Synergetics USA click here. For more ratings news on Synergetics USA click here.
Shares of Synergetics USA closed at $3.66 yesterday, with a 52 week range of $3.30-$7.55.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
Analyst, Raymond Myers, said, "Meeting with Management at the Benchmark Investor One-on-One Conference on May 31 strengthen our conviction that the recently pre-announced F3Q miss is a short term distraction to an otherwise sound strategic outlook. In the near-term, Management is confident that current quarter results will return to their historically robust growth trajectory. More important, Synergetics is making inroads with VersaPACK and is confident in VersaVIT’s approval in as little as 30-days. Advancing these key strategic initiatives outweighs short term quarterly inconsistency, in our view. We believe last week’s stock reaction creates an outstanding buying opportunity with SURG shares trading at 8.5x EV/EPS forecast in F2013."
For an analyst ratings summary and ratings history on Synergetics USA click here. For more ratings news on Synergetics USA click here.
Shares of Synergetics USA closed at $3.66 yesterday, with a 52 week range of $3.30-$7.55.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- Morgan Stanley Says Tesla (TSLA) 'Top Pick in U.S. Autos'
- Jefferies Buyers of Jack In The Box (JACK) on Solid Results
- Pier 1 Imports (PIR) Sets Sights on Growing Ecommerce
Create E-mail Alert Related Categories
Analyst Comments
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
